Literature DB >> 18706172

[Clinical analysis of childhood acute generalized exanthematous pustulosis].

Jiang-Lin Zhang1, Xiang Chen, Ji Li, Hong-Fu Xie.   

Abstract

OBJECTIVE: To describe the etiology, clinical features and treatment of childhood acute generalized exanthematous pustulosis (AGEP).
METHODS: Clinical data from 20 cases of childhood acute generalized exanthematous pustulosis from 1990 to 2008 were retrospectively reviewed.
RESULTS: Eighteen cases had a history of medication, including the use of penicillin (n=6), cephalosporins (n=3), sulphonamides (n=2), algopyrin (n=2), vaccines (n=2 ) and anti-cold drugs (n=3). Fever and generalized erythematous pustules were observed in all 20 cases. Histopathologic examination revealed spongiform superficial pustules and papillary edema. The patients were asked to stop taking suspected sensitizing drugs and received glucocorticoid treatment (1-2 mg/kg daily). After 3-5 days of the treatment, symptoms were improved and the dosage of glucocorticoid was gradually reduced. All patients were healed within 20 days after treatment.
CONCLUSIONS: The cause of AGEP is mainly attributed to the use of antibiotics, sulphonamides, antipyretic analgesics and vaccines in children. AGEP is characterized by fever and widespread pustular eruption of the skin. Removal of sensitizing factors and glucocorticoid administration is important in the treatment of AGEP in children.

Entities:  

Mesh:

Year:  2008        PMID: 18706172

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  2 in total

1.  Acute Generalised Exanthematous Pustulosis: An Update.

Authors:  Abhishek De; Sudip Das; Aarti Sarda; Dayamay Pal; Projna Biswas
Journal:  Indian J Dermatol       Date:  2018 Jan-Feb       Impact factor: 1.494

2.  Three cases of vesiculobullous non-IgE-mediated cutaneous reactions to tozinameran (Pfizer-BioNTech COVID-19 vaccine).

Authors:  L Juay; N S Chandran
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-08-16       Impact factor: 9.228

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.